| MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment |
13 |
| The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know |
11 |
| Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease |
10 |
| Will CAR T cell therapy have a role in AML? Promises and pitfalls |
10 |
| Immune reconstitution after T-cell replete HLA-haploidentical transplantation |
9 |
| Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease |
9 |
| Complement in Pathophysiology and Treatment of Transplant -Associated Thrombotic Microangiopathies |
9 |
| Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods |
8 |
| Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study |
7 |
| Fetal Hemoglobin Induction by Epigenetic Drugs |
7 |
| Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin Disease |
7 |
| Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple Myeloma |
7 |
| Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria |
7 |
| Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease |
6 |
| MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical Tool |
6 |
| Maintenance therapy in acute myeloid leukemia: What is the future? |
6 |
| The emerging role of measurable residual disease detection in AML in morphologic remission |
6 |
| Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome |
6 |
| Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results |
5 |
| Shifting paradigms in the treatment of older adults with AML |
5 |
| A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy |
5 |
| Genetic therapies for sickle cell disease |
5 |
| Congenital Defects in the Expression of the Glycosylphosphatidylinositol-Anchored Complement Regulatory Proteins CD59 and Decay-Accelerating Factor |
5 |
| Mass spectrometry and proteomics in hematology |
5 |
| When there is no match, the game is not over: Alternative donor options for hematopoietic stem cell transplantation in sickle cell disease |
4 |
| Anticomplement Treatment in Atypical and Typical Hemolytic Uremic Syndrome |
4 |
| Acquired and germline predisposition to bone marrow failure: Diagnostic features and clinical implications |
4 |
| Sickle cell disease: Translating clinical care to low-resource countries through international research collaborations |
4 |
| Haploidentical donor transplants for severe aplastic anemia |
4 |
| Poor graft function after allogeneic hematopoietic stem cell transplantation-an old complication with new insights |
4 |
| Who is the best donor for haploidentical stem cell transplantation? |
3 |
| Is human leukocyte antigen-matched sibling donor transplant always better than haploidentical allograft? |
3 |
| Genetic and epigenetic determinants of AML pathogenesis |
3 |
| Autologous hematopoietic cell transplantation for AML in first remission - An abandoned practice or promising approach? |
3 |
| Acquired Hemophilia A in Aged People: A Systematic Review of Case Reports and Case Series |
3 |
| Patient assistance programs: a valuable, yet imperfect, way to ease the financial toxicity of cancer care |
3 |
| Philadelphia chromosome-like acute lymphoblastic leukemia: A review of the genetic basis, clinical features, and therapeutic |
3 |
| Increased cardiovascular comorbidities in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia presenting with systemic inflammatory and autoimmune manifestations |
3 |
| Iron deficiency workup reveals high incidence of autoimmune gastritis with parietal cell antibody as reliable screening test |
3 |
| The challenging task of enumerating blasts in the bone marrow |
3 |
| Molecular assessment of clonality in lymphoid neoplasms |
3 |
| Minimal residual disease in multiple myeloma: use of magnetic resonance imaging |
3 |
| Minimal Residual Disease Detection by Flow Cytometry in Multiple Myeloma: Why and How? |
3 |
| Ten Years of Clinical Experience With Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria |
3 |
| Advances in diagnosis of mastocytosis and hypereosinophilic syndrome |
2 |
| The current approach to the diagnosis of myelodysplastic syndromes |
2 |
| Diagnosis and classification of lymphoma: Impact of technical advances |
2 |
| Genetic studies in the evaluation of myeloproliferative neoplasms |
2 |
| Next generation sequencing in hematolymphoid neoplasia |
2 |
| Novel Sickle Cell Disease Therapies: Targeting Pathways Downstream of Sickling |
2 |
